Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNon-cash ItemsShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Roivant Sciences (ROIV) Gains from Sales and Divestitures (2022 - 2025)

Historic Gains from Sales and Divestitures for Roivant Sciences (ROIV) over the last 4 years, with Q2 2025 value amounting to $297795.0.

  • Roivant Sciences' Gains from Sales and Divestitures fell 8661.85% to $297795.0 in Q2 2025 from the same period last year, while for Jun 2025 it was $297795.0, marking a year-over-year decrease of 8661.85%. This contributed to the annual value of $6.1 million for FY2025, which is 1102.56% down from last year.
  • Latest data reveals that Roivant Sciences reported Gains from Sales and Divestitures of $297795.0 as of Q2 2025, which was down 8661.85% from $6.1 million recorded in Q1 2025.
  • Roivant Sciences' 5-year Gains from Sales and Divestitures high stood at $12.0 million for Q1 2023, and its period low was $297795.0 during Q2 2025.
  • For the 4-year period, Roivant Sciences' Gains from Sales and Divestitures averaged around $4.8 million, with its median value being $4.5 million (2023).
  • As far as peak fluctuations go, Roivant Sciences' Gains from Sales and Divestitures skyrocketed by 368.1% in 2023, and later plummeted by 8661.85% in 2025.
  • Roivant Sciences' Gains from Sales and Divestitures (Quarter) stood at $5.8 million in 2022, then fell by 4.56% to $5.5 million in 2023, then decreased by 10.21% to $4.9 million in 2024, then tumbled by 93.97% to $297795.0 in 2025.
  • Its last three reported values are $297795.0 in Q2 2025, $6.1 million for Q1 2025, and $4.9 million during Q4 2024.